Pantoprazole Teva (Pantoprazole)

Pantoprazole Teva is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates healing of erosive lesions in the oesophagus.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours.
• Healing of duodenal ulcers: supports ulcer healing and reduces recurrence risk.
• Prevention of NSA‑induced gastric ulcers: lowers the risk of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs.

• Pantoprazole selectively and irreversibly binds to the H⁺/K⁺‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces both basal and stimulated gastric acidity, allowing mucosal healing and symptom control.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation: occasional.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reactions (e.g., anaphylaxis, angio‑edema).
• Clostridioides difficile‑associated colitis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Acute interstitial nephritis.
• Fracture risk with long‑term high‑dose therapy.
• Liver enzyme elevations.

When prescribing Pantoprazole Teva, clinicians should consider several safety aspects:

• Assess renal and hepatic function: dose adjustment may be needed in severe impairment.
• Review concomitant medications: potential for drug‑drug interactions, especially with drugs requiring acidic pH for absorption.
• Monitor long‑term users: watch for magnesium deficiency, bone density changes, and possible infections.
• Use caution in pregnancy: only if the potential benefit justifies the risk.
• Avoid in patients with known hypersensitivity to pantoprazole or other PPIs.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Antifungal agents such as ketoconazole or itraconazole: reduced absorption and efficacy.
• HIV protease inhibitors (e.g., atazanavir, nelfinavir): markedly decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR; monitor coagulation parameters.
• Methotrexate: reduced clearance may raise toxicity risk.
• Digoxin: slight increase in serum levels; observe for signs of toxicity.